Information is solely for medical professionals
Beifuxin Gel
Recombinant Bovine Basic Fibroblast Growth Factor Gel
/
Specification 21000IU/5g and 42000IU/10g
Beifuxin gel is a genetically engineered new drug developed and manufactured by Zhuhai Essex Bio-Pharmaceutical Co., Ltd..

The API of Beifuxin is recombinant bovine basic fibroblast growth factor (rb-bFGF) - a multifunctional growth factor with a wide range of bioactivity, which can stimulate the proliferation and differentiation of cells involved in wound healing
Mechanism
The API of Beifuxin is recombinant bovine basic fibroblast growth factor (rb-bFGF), which can stimulate the repair and regeneration of tissues and cells derived from the mesoderm and ectoderm (such as epithelial cells, dermal cells, fibroblasts, vascular endothelial cells, osteoblasts, nerve cells etc.). The specific combination of rb-bFGF with the wounded target cell surface can trigger the cells to repair actively and stimulate cell division, proliferation, migration and differentiation, so as to accelerate wound healing and improve the healing quality.
Features
· A new water-soluble gel that can control the release of the active ingredient
· Accelerate wound healing
· Shortening the healing time and reduce scar formation
· Safe and effective treatment without any side effect
Clinical Application
· Burn and scald wounds: including shallow II degree and deep II degree wounds, granulation wounds and inhalation injuries.
· Acute wounds: bruises, contusions, combined injuries and cuts.
· Surgical incisions: incisions of surgery, orthopedics, gynaecology (such as lateral episiotomy and cesarean incision), otolaryngology, urology and proctology.
· Chronic wounds: diabetic ulcers, vascular ulcers, radiochemotherapy ulcers, bedsores, fistulas, residual wounds and cervical erosions.
· Skin grafting: skin donor site, skin grafting site, skin flap handling.
· Other applications: after plastic surgery, skin resurfacing, dermabrasion, nevus removal and laser therapy wounds.
NDRL
《National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (2019)》
Medical Guidelines
· Chinese Dermatologist Consensus about Application of Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) for Laser and IPLS Treatment and Skin Barrier Repairment (2019)
· Clinical Guidelines for Use of Exogenous Growth Factors in Skin Wounds, Chin J Burns (2017)
· Expert Advice on Diagnosis and Treatment of Pemphigus Vulgaris (2016)
· Chinese Guidelines for Diagnosis and Treatment of Skin Wounds (2015)
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
市区开早餐店赚钱吗 泳坛夺金组选中奖规则 在家做手工赚钱 幸运飞艇官方高倍平台 下载辽宁十一选五开奖直播 河南快三综合走势图 河南快三app下载 股票技术指标论坛 正规股票配资平台 北京极速赛车网站开奖 湖北11选五直选三走势图